half life of oral semaglutide Will be a game-changer in the management type 2 diabetes in primary care? A Review of the Oral

This article explores early warning Read More Incretin Therapy Selection in High-Risk Patients: What New Outcomes Data Suggest May 4, 2026 Articles, Cardiology, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 877 views Choosing the right treatment for patients with both diabetes and heart disease can feel like walking a tightrope

However, this treatment strategy is still in the early stages although the National Institutes for Health (NIH) recently has invested in research in the area of personalized nutrition

References Kroemer, G., Lopez-Otin, C., Madeo, F

To be or not to be